Latigo Biotherapeutics (NASDAQ:LTGO) Shares Down 22.4% – What’s Next?

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)’s stock price traded down 22.4% during trading on Thursday. The company traded as low as $10.24 and last traded at $10.89. Approximately 51,744 shares were traded during mid-day trading, a decline of 82% from the average session volume of 280,885 shares. The stock had previously closed at $14.04.

Latigo Biotherapeutics News Roundup

Here are the key news stories impacting Latigo Biotherapeutics this week:

• Positive Sentiment: Latigo reported a third-quarter loss of $0.55 per share, beating analyst estimates by $0.12. Earnings estimate beat
• Positive Sentiment: The company says Phase 3 bunionectomy and open-label safety trials for onzotrigine remain on track to begin, with topline results expected in the second half of 2027. Third-quarter results and business highlights
• Positive Sentiment: Latigo appointed pain-sector executive Todd Smith as president and CEO. His commercialization experience could support the company’s plans to advance and potentially commercialize non-opioid pain treatments. CEO appointment
• Neutral Sentiment: LTGO trading was temporarily paused twice under limit-up/limit-down volatility rules. The pauses indicate heightened volatility, not a specific direction or cause.
• Negative Sentiment: Despite beating estimates, Latigo still reported a quarterly loss, and the expected Phase 3 readout is not until the second half of 2027, leaving substantial time and clinical-development risk before a potential catalyst. Third-quarter and nine-month results

Analyst Ratings Changes

Several equities research analysts have commented on LTGO shares. Weiss Ratings assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set a “sell (e-)” rating on the stock. Wall Street Zen raised Latigo Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group initiated coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price target for the company. The Goldman Sachs Group assumed coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $73.00 price objective on the stock. Finally, Guggenheim started coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $50.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.25.

Latigo Biotherapeutics Trading Down 3.2%

The company has a market capitalization of $835.38 million and a price-to-earnings ratio of -0.24. The company has a 50-day moving average of $17.95.

Latigo Biotherapeutics (NASDAQ:LTGO) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.55) earnings per share (EPS) for the quarter.

Insider Activity at Latigo Biotherapeutics

In related news, major shareholder Foresite Capital Management V, purchased 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James B. Tananbaum bought 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Latigo Biotherapeutics

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing non-opioid treatments for pain. The company focuses on therapies designed to selectively target Nav1.8, a sodium channel expressed in peripheral sensory neurons that plays an important role in the transmission of pain signals.

Latigo’s lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for the treatment of acute and chronic pain conditions. By targeting pain signaling outside the central nervous system, the company aims to develop alternatives to opioid medicines and other pain treatments that may carry significant safety or tolerability concerns.